Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
data privacy protection Impressum
Home
Research
Research Topics
Functional and Structural Genomics
Mechanisms of Leukemogenesis
Publications

Research

Publications

List of Publications

Selected Articles

  1. Mertens, D. and S. Stilgenbauer (2017). "Ibrutinib-resistant CLL: unwanted and unwonted!" Blood129(11): 1407-1409., IF 13.164

  2. C.C. Oakes, M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C. Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz, S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, 48(3):253-64, IF 29.352

  3. D.A. Landau*, E. Tausch*, A.N. Taylor-Weiner*, C. Stewart, J. Reiter, J. Bahlo, S. Kluth, I. Bozic, M. Lawrence, S. Bottcher, K. Cibulskis, D. Mertens, C. Sougnez, M. Rosenberg, J.M. Hess, S.L. Carter, J. Edelmann, S. Kless, A. Fink, K. Fischer, S. Gabriel, E. Lander,  M. Nowak, H. Dohner, M. Hallek, D. Neuberg**,   G. Getz**, S. Stilgenbauer** and C.J. Wu** (2015). „Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.” Nature, 526(7574):525-30, IF 41.456

  4. Zenz, T., D. Mertens, R. Kuppers, H. Dohner and S. Stilgenbauer (2010). From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:1: 37-50, IF 29.538

  5. Viola Close, William Close, Sabrina Julia Kugler, Michaela Reichenzeller, Deyan Yordanov Yosifov, Johannes Bloehdorn, Leiling Pan, Eugen Tausch, Mike-Andrew Westhoff, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, and Daniel Mertens (2018). “FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.” Blood, 2018 pre-publication

  6. Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer§, Daniel Mertens, „From Biology to Therapy: The CLL Success Story.”, Hemasphere 2019, doi: 10.1097/HS9.0000000000000175

Original Articles

  1. Wolf, C., A. Garding, K. Filarsky, J. Bahlo, S. Robrecht, N. Becker, M. Zucknick, A. Rouhi, A. Weigel, R. Claus, D. Weichenhan, B. Eichhorst, K. Fischer, M. Hallek, F. Kuchenbauer, C. Plass, H. Dohner, S. Stilgenbauer, P. Lichter and D. Mertens (2018). "NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib." Int J Cancer 142(2): 322-333. IF 6,513

  2. Mettang, M., V. Meyer-Pannwitt, G. Karpel-Massler, S. Zhou, N. O. Carragher, K. J. Fohr, B. Baumann, L. Nonnenmacher, S. Enzenmuller, M. Dahlhaus, M. D. Siegelin, S. Stroh, D. Mertens, P. Fischer-Posovszky, E. M. Schneider, M. E. Halatsch, K. M. Debatin and M. A. Westhoff (2018). "Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach." Sci Rep 8(1): 5527. IF 4,259

  3.  Walliser, C., Hermkes, E., Schade, A, Wiese, S., Deinzer, J., Zapatka, M., Désiré, L., D. Mertens, Stilgenbauer, S., and Gierschik, P. (2016). „The Phospholipase C-g2 Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic Leukemia Patients are Hypersensitive to the Rho GTPase Rac2.” J Biol Chem 291(42): 22136-22148., IF 4.258

  4. K. Filarsky, A. Garding, N. Becker, C. Wolf, M. Zucknick, R. Claus, D. Weichenhan, C. Plass, H. Döhner, S. Stilgenbauer, P. Lichter and D. Mertens (2016). „Krüppel-Like Factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling.“ Haematologica, 101(6):e249-53, IF 5.814

  5. C.C. Oakes, M. Seifert, Y. Assenov, L. Gu, M. Przekopowitz, A.S. Ruppert, Q. Wang, C. Imbusch, A. Serva, S. Koser, D. Brocks, D. Lipka, O. Bogatyrova, D. Mertens, M. Zapatka, P. Lichter, H. Döhner, R. Küppers, T. Zenz, S. Stilgenbauer, J.C. Byrd and C. Plass (2015). “Progressive epigenetic programming during B cell maturation is reflected in a continuum of epigenetic disease phenotypes in chronic lymphocytic leukemia.” Nature Genetics, 48(3):253-64, IF 29.352

  6. D.A. Landau*, E. Tausch*, A.N. Taylor-Weiner*, C. Stewart, J. Reiter, J. Bahlo, S. Kluth, I. Bozic, M. Lawrence, S. Bottcher, K. Cibulskis, D. Mertens, C. Sougnez, M. Rosenberg, J.M. Hess, S.L. Carter, J. Edelmann, S. Kless, A. Fink, K. Fischer, S. Gabriel, E. Lander,  M. Nowak, H. Dohner, M. Hallek, D. Neuberg**,   G. Getz**, S. Stilgenbauer** and C.J. Wu** (2015). „Somatic mutations driving chronic lymphocytic leukemia and their evolution in disease progression and relapse.” Nature, 526(7574):525-30, IF 41.456

  7. Opel, D., Schnaiter, A., Dodier, D., Jovanovic, M., Gerhardinger, A., Idler, I., Mertens, D., Bullinger, L., Stilgenbauer, S., Fulda, S. (2015). „Targeting inhibitor of apoptosis proteins by Smac mimetic elicits death in poor prognostic subgroups of chronic lymphocytic leukemia.“ Int. J. Cancer, 137(12):2959-70, IF 5.007.

  8. Baer, C., Oakes, CC, Ruppert, AS., Claus, R., Kim-Wanner, SZ., Mertens, D., Zenz, T., Stilgenbauer, S.,Byrd, JC. and Plass, C. (2015). „Epigenetic silencing of miR-708 enhances NF-kB signaling in chronic lymphocytic leukemia.“ Int J Cancer, 137(6):1352-61, IF 5.007

  9. Bhattacharya, N., M. Reichenzeller, M. Caudron-Herger, S. Haebe, N. Brady, S. Diener, M. Nothing, H. Dohner, S. Stilgenbauer, K. Rippe and D. Mertens (2015). "Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6." Int J Cancer, 136(1):65-73,  IF 6.198

  10. Stilgenbauer, S., A. Schnaiter, P. Paschka, T. Zenz, M. Rossi, K. Dohner, A. Buhler, S. Bottcher, M. Ritgen, M. Kneba, D. Winkler, E. Tausch, P. Hoth, J. Edelmann, D. Mertens, L. Bullinger, M. Bergmann, S. Kless, S. Mack, U. Jager, N. Patten, L. Wu, M. K. Wenger, G. Fingerle-Rowson, P. Lichter, M. Cazzola, C. M. Wendtner, A. M. Fink, K. Fischer, R. Busch, M. Hallek and H. Dohner (2014). "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial." Blood, in press. IF 9.060

  11. Skorka, K., N. Bhattacharya, P. Wlasiuk, M. Kowal, D. Mertens, A. Dmoszynska and K. Giannopoulos (2014). "Thalidomide regulation of NF-kappaB proteins limits Tregs activity in chronic lymphocytic leukemia." Adv Clin Exp Med 23(1): 25-32., IF 0.293

  12. C. Oakes, R. Claus, L. Gu, Y. Assenov, J. Hüllein, M. Zucknick, D. Brocks, O. Bogatyrova, C. Schmidt, L. Rassenti, TJ. Kipps, Mertens, D., P. Lichter, H. Dohner, S. Stilgenbauer, JC. Byrd, T. Zenz and C. Plass (2013) Heterogeneity and evolution of DNA methylation are linked to genetic aberrations in chronic lymphocytic leukemia, Cancer Disvovery,  4(3):348-361, IF 10.143

  13. Allegra, D., Bilan, V., Garding, A., Döhner, H., Stilgenbauer, S., Kuchenbauer, F., Mertens, D. (2013), Defective DROSHA processing contributes to downregulation of miR-15/-16 in chronic lymphocytic leukemia, Leukemia, 28(1):98-107, IF 10.164

  14. Schnaiter, A., Pascka, P.,  Rossi, M., Zenz, T., Bühler, A., Winkler, D., Cazzola, M., Döhner, K., Edelmann, J., Mertens, D., Kless, S., Mack, S., Busch, E., Hallek, M., Döhner, H., Stilgenbauer, S. (2013), NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG, Blood,122(7):1266-1270, IF 9.060

  15. Wei, QX., Claus, R., Hielscher, T., Mertens, D., Raval, A., Oakes, CC., Tanner, ST., de la Chapelle, A., Byrd, JC., Stilgenbauer, S., Plass, C. (2013), Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia, PLOS ONE, 8(1) e55261, IF 4.091

  16. Garding, A., Bhattacharya, N., Claus, R., Ruppel, M., Tschuch, C., Filarsky, K., Idler, I., Zucknick, M., Caudron-Herger, M., Oakes, C., Fleig, V., Keklikoglou, I., Allegra, D., Serra, L., Thakurela, S., Tiwari, V., Weichenhan, D., Benner, A., Radlwimmer, B., Zentgraf, H., Wiemann, S., Rippe, K., Plass, C., Döhner, H., Lichter, P. Stilgenbauer, S., Mertens, D. (2013), Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB, PLOS Genetics, 9(4): e1003373, IF 8.694

  17. Jebaraj, BMC., Kienle, D., Lechel, A., Mertens, D., Heuberger, M., Ott, D., Rosenwald, A., Barth, T., Möller, P., Zenz, T., Döhner, H., Stilgenbauer, S.. (2013), "Telomere Length in Mantle Cell Lymphoma", Blood, 121(7):1184-7, IF 8.989

  18. Garding, A., Bhattacharya, N., Haebe, S., Mueller, F., Weichenhan, D., Idler, I., Ickstadt, K., Stilgenbauer, S. & Mertens, D. (2013) "TCL1A and ATM are coexpressed in chronic lymphocytic leukemia cells without deletion of 11q." Haematologica, 98(2):269-73. IF 6.416

  19. Faber, K., Bullinger, L., Ragu, C., Garding, A., Mertens, D., Miller, C., Martin, D., Walcher, D., Döhner, K., Döhner, H., Claus, R., Plass, C., Sykes, S.M., Lane, S.W., Scholl, C., & Fröhling, S. (2012), “Myeloid leukemogenesis by CDX2 involves repression of KLF4 and deregulated PPAR signalling”, JCI, 123(1): 299-314, IF 13.069

  20. Edelmann, J., Holzmann, K., Miller, F., Winkler, D., Bühler, A., Zenz, T., Bullinger, L., Kühn, M.W.M., Gerhardinger, A., Blöhdorn, J., Radtke, I., Su, X., Ma, J., Pounds, S., Hallek, M., Lichter, P., Korbel, J., Busch, R., Mertens, D., Downing, J.R., Stilgenbauer, S., & Döhner H. (2012), “High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations”, Blood, 120(24):4783-94, IF 8.989

  21. Claus, R., Lucas, D. M., Stilgenbauer, S., Ruppert, A. S., Yu, L., Zucknick, M., Mertens, D., Buhler, A., Oakes, C. C., Larson, R. A., Kay, N. E., Jelinek, D. F., Kipps, T. J., Rassenti, L. Z., Gribben, J. G., Dohner, H., Heerema, N. A., Marcucci, G., Plass, C. & Byrd, J. C. (2012) "Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia." J Clin Oncol, 30(20):2483-91. IF 18.970

  22. Grasedieck, S., Scholer, N., Bommer, M., Niess, J. H., Tumani, H., Rouhi, A., Bloehdorn, J., Liebisch, P., Mertens, D., Dohner, H., Buske, C., Langer, C. & Kuchenbauer, F. (2012) "Impact of serum storage conditions on microRNA stability." Leukemia, 26(11):2414-6. IF 8.966

  23. Grzywnowicz, M., Zaleska, J., Mertens, D., Tomczak, W., Wlasiuk, P., Kosior, K., Piechnik, A., Bojarska-Junak, A., Dmoszynska, A. & Giannopoulos, K. (2012) "Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia." PloS one, 7, e35178. IF 4.411

  24. Allegra, D. & Mertens, D. (2011) "In-vivo quantification of primary microRNA processing by Drosha with a luciferase based system." Biochemical and biophysical research communications, 406, 501-505. IF 2.595

  25. Bhattacharya, N., Diener, S., Idler, I. S., Rauen, J., Habe, S., Busch, H., Habermann, A., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Nurse-like cells show deregulated expression of genes involved in immunocompetence." Br J Haematol, 154, 349-356. IF 4.597

  26. Mohr, J., Helfrich, H., Fuge, M., Eldering, E., Buhler, A., Winkler, D., Volden, M., Kater, A. P., Mertens, D., Te Raa, D., Dohner, H., Stilgenbauer, S. & Zenz, T. (2011) "DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing." Blood, 117, 1622-1632. IF 10.555

  27. Wittig-Blaich, S. M., Kacprzyk, L. A., Eismann, T., Bewerunge-Hudler, M., Kruse, P., Winkler, E., Strauss, W. S., Hibst, R., Steiner, R., Schrader, M., Mertens, D., Sultmann, H. & Wittig, R. (2011) "Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells." Neoplasia, 13, 579-589. IF 5.476

  28. Bhattacharya, N., Diener, S., Idler, I. S., Barth, T. F., Rauen, J., Habermann, A., Zenz, T., Moller, P., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14+ cells from peripheral blood." Leukemia, 25, 722-726. IF 8.296

  29. Bhattacharya, N., Sarno, A., Idler, I. S., Fuhrer, M., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay." Int J Cancer, 127, 404-411. IF 4.722

  30. Philippen, A., Diener, S., Zenz, T., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL)." Br J Haematol, 150, 633-636. IF 4.597

  31. Winkler, D., Schneider, C., Zucknick, M., Bogelein, D., Schulze, K., Zenz, T., Mohr, J., Philippen, A., Huber, H., Buhler, A., Habermann, A., Benner, A., Dohner, H., Stilgenbauer, S. & Mertens, D. (2010) "Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk." Haematologica, 95, 1880-1888. IF 6.416

  32. Zenz, T., Mohr, J., Edelmann, J., Sarno, A., Hoth, P., Heuberger, M., Helfrich, H., Mertens, D., Dohner, H. & Stilgenbauer, S. (2009) "Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway." Leuk Lymphoma, 50, 510-513. IF 2.397

  33. Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Buhler, A., Kienle, D., Winkler, D., Durig, J., van Oers, M. H., Mertens, D., Dohner, H.& Stilgenbauer, S. (2009) "miR-34a as part of the resistance network in chronic lymphocytic leukemia." Blood, 113, 3801-3808. IF 10.555

  34. Giannopoulos, K., Mertens, D., Buhler, A., Barth, T. F., Idler, I., Moller, P., Krober, A., Greiner, J., Chocholska, S., Dmoszynska, A., Rolinski, J., Dohner, H., Stilgenbauer, S. & Schmitt, M. (2009) "The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia." Leukemia, 23, 519-527. IF 8.296

  35. Loeder, S., Zenz, T., Schnaiter, A., Mertens, D., Winkler, D., Dohner, H., Debatin, K. M., Stilgenbauer, S. & Fulda, S. (2009) "A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia." Cancer Res, 69, 8977-8986. IF 7.543

  36. Idler, I., Giannopoulos, K., Zenz, T., Bhattacharya, N., Nothing, M., Dohner, H., Stilgenbauer, S. & Mertens, D. (2009) "Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells." Br J Haematol, 148, 948-950. IF 4.597

  37. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. & Stilgenbauer, S. (2009) "Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial." Blood, 114, 2589-2597. IF 10.555

  38. Tschuch, C., Schulz, A., Pscherer, A., Werft, W., Benner, A., Hotz-Wagenblatt, A., Barrionuevo, L. S., Lichter, P. & Mertens, D. (2008) "Off-target effects of siRNA specific for GFP." BMC Mol Biol, 9, 60. IF 2.848

  39. Kalla, C., Scheuermann, M. O., Kube, I., Schlotter, M., Mertens, D., Dohner, H., Stilgenbauer, S. & Lichter, P. (2007) "Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B." Eur J Cancer, 43, 1328-1335. IF 4.121

  40. Prowatke, I., Devens, F., Benner, A., Grone, E. F., Mertens, D., Grone, H. J., Lichter, P. & Joos, S. (2007) "Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays." Br J Cancer, 96, 82-88. IF 4.346

  41. Henrich, K. O., Fischer, M., Mertens, D., Benner, A., Wiedemeyer, R., Brors, B., Oberthuer, A., Berthold, F., Wei, J. S., Khan, J., Schwab, M. & Westermann, F. (2006) "Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients." Clin Cancer Res, 12, 131-138. IF 6.747

  42. Kienle, D., Benner, A., Krober, A., Winkler, D., Mertens, D., Buhler, A., Seiler, T., Jager, U., Lichter, P., Dohner, H. & Stilgenbauer, S. (2006) "Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes." Blood, 107, 2090-2093. IF 10.555

  43. Adamowicz, M., Radlwimmer, B., Rieker, R. J., Mertens, D., Schwarzbach, M., Schraml, P., Benner, A., Lichter, P., Mechtersheimer, G. & Joos, S. (2006) "Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas." Genes Chromosomes Cancer, 45, 829-838. IF 3.858

  44. Wolf, S., Mertens, D., Pscherer, A., Schroeter, P., Winkler, D., Grone, H. J., Hofele, C., Hemminki, K., Kumar, R., Steineck, G., Dohner, H., Stilgenbauer, S. & Lichter, P. (2006) "Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer." Int J Cancer, 118, 1831-1835. IF 4.722

  45. Mannherz, O., Mertens, D., Hahn, M. & Lichter, P. (2006) "Functional screening for proapoptotic genes by reverse transfection cell array technology." Genomics, 87, 665-672. IF 3.327

  46. Mertens, D., Wolf, S., Tschuch, C., Mund, C., Kienle, D., Ohl, S., Schroeter, P., Lyko, F., Dohner, H., Stilgenbauer, S. & Lichter, P. (2006) "Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism." Proc Natl Acad Sci U S A, 103, 7741-7746. IF 9.432

  47. Kienle, D. L., Korz, C., Hosch, B., Benner, A., Mertens, D., Habermann, A., Krober, A., Jager, U., Lichter, P., Dohner, H. & Stilgenbauer, S. (2005) "Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes." J Clin Oncol, 23, 3780-3792. IF 17.793

  48. Kalla, C., Nentwich, H., Schlotter, M., Mertens, D., Wildenberger, K., Dohner, H., Stilgenbauer, S. & Lichter, P. (2005) "Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes." Genes Chromosomes Cancer, 42, 128-143. IF 3.858

  49. Mertens, D., Wolf, S., Schroeter, P., Schaffner, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2002) "Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia." Blood, 99, 4116-4121. IF 10.555

  50. Korz, C., Pscherer, A., Benner, A., Mertens, D., Schaffner, C., Leupolt, E., Dohner, H., Stilgenbauer, S.& Lichter, P. (2002) "Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes." Blood, 99, 4554-4561. IF 10.555

  51. Wolf, S., Mertens, D., Schaffner, C., Korz, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2001) "B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions." Hum Mol Genet, 10, 1275-1285. IF 7.386

  52. Mertens, D., Wolf, S., Bullinger, L., Ohl, S., Schaffner, C., Dohner, H., Stilgenbauer, S. & Lichter, P. (2000) "BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22- p31, BCMSUN-like." Int J Cancer, 88, 692-697. IF 4.722

  53. Bullinger, L., Leupolt, E., Schaffner, C., Mertens, D., Bentz, M., Lichter, P., Dohner, H. & Stilgenbauer, S. (2000) "BCL10 is not the gene inactivated by mutation in the 1p22 deletion region in mantle cell lymphoma." Leukemia, 14, 1490-1492. IF 8.296

  54. Lammer, C., Wagerer, S., Saffrich, R., Mertens, D., Ansorge, W. & Hoffmann, I. (1998) "The cdc25B phosphatase is essential for the G2/M phase transition in human cells." J Cell Sci, 111 ( Pt 16), 2445-2453. IF 6.144

  55. Viola Close, William Close, Sabrina Julia Kugler, Michaela Reichenzeller, Deyan Yordanov Yosifov, Johannes Bloehdorn, Leiling Pan, Eugen Tausch, Mike-Andrew Westhoff, Hartmut Döhner, Stephan Stilgenbauer, Franz Oswald, and Daniel Mertens (2018). “FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.” Blood, 2018 pre-publication

  56. Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer§, Daniel Mertens, „From Biology to Therapy: The CLL Success Story.”, Hemasphere 2019, doi: 10.1097/HS9.0000000000000175

Reviews

  1. Mertens, D. and S. Stilgenbauer (2017). "Ibrutinib-resistant CLL: unwanted and unwonted!" Blood 129(11): 1407-1409., IF 13.164

  2. Meyer-Pannwitt, V., Steinbrecher, D., Stilgenbauer, S., Mertens, D. (2016). "Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for CLL?" Leukemia & Lymphoma, 58(1): 6-7., IF 3.093

  3. E. Tausch, D. Mertens, S. Stilgenbauer (2016). „Genomic Features: Impact on Pahtogenesis and Treatment of Chronic Lymphocytic Leukemia.” Oncol Res Treat, 39(1-2):34-40. IF 1.333

  4. Mertens, D. and S. Stilgenbauer (2014). "Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?" J Clin Oncol, 32(9): 869-872, IF 18.038

  5. Tausch, E., Mertens, D. and Stilgenbauer, S. (2014). "Advances in treating chronic lymphocytic leukemia." F1000Prime Reports,  6(65), no IF

  6. Grasedieck, S., Sorrentino, A., Langer, C., Buske, C., Döhner, H., Mertens, D., Kuchenbauer, F. (2013) "Circulating microRNAs in Hematological Diseases: Principles, Challenges and Perspectives." Blood, 121(25):4977-4984, IF 9.989

  7. Kugler, S., Schnaiter, A., Stilgenbauer, S.&  Mertens, D. (2013) "Missing the Notch in NOTCH1" Leukemia & Lymphoma, 54(8):1579-1580. IF 2.580

  8. Mertens, D.& Stilgenbauer, S. (2012) "CLL and deletion 13q14: merely the miRs?" Blood, 119, 2974-2975. IF 10.558

  9. Idler, I., Bhattacharya, N., Dohner, H., Stilgenbauer, S. & Mertens, D. (2011) "Immune modulatory agents in hematopoietic malignancies." Cancer treatment reviews, 37 Suppl 1, S2-7. IF 6.811

  10. Schnaiter, A., Mertens, D. &Stilgenbauer, S. (2011) "Genetics of chronic lymphocytic leukemia." Clinics in laboratory medicine, 31, 649-658, ix. IF 1.966

  11. Stilgenbauer, S. & Mertens, D. (2011) "Toward chemotherapy-free treatment of CLL." Blood, 118, 3451-3452. IF 10.558

  12. Mertens, D., Bullinger, L. & Stilgenbauer, S. (2011) "Chronic lymphocytic leukemia--genomics lead the way." Haematologica, 96, 1402-1405. IF 6.532

  13. Giannopoulos, K., Mertens, D., Stilgenbauer, S. (2011), Treating chronic lymphocytic leukemia with Thalidomide and Lenalidomide, Current Opinion in Pharmacotherapy, 12(18):2857-64, IF 2.403

  14. Zenz, T., Mertens, D., Dohner, H.& Stilgenbauer, S. (2011) "Importance of genetics in chronic lymphocytic leukemia." Blood reviews, 25, 131-137. IF 10.558

  15. Zenz, T., Mertens, D. &Stilgenbauer, S. (2010) "Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia." Haematologica, 95, 1441-1443. IF 6.416

  16. Zenz, T., Frohling, S., Mertens, D., Dohner, H. & Stilgenbauer, S. (2010) "Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)." Best Pract Res Clin Haematol, 23, 71-84. IF 3.134

  17. Zenz, T., Mertens, D., Kuppers, R., Dohner, H.& Stilgenbauer, S. (2010) "From pathogenesis to treatment of chronic lymphocytic leukaemia." Nat Rev Cancer, 10, 37-50. IF 29.538

  18. Mertens, D., Philippen, A., Ruppel, M., Allegra, D., Bhattacharya, N., Tschuch, C., Wolf, S., Idler, I., Zenz, T.& Stilgenbauer, S. (2009) "Chronic lymphocytic leukemia and 13q14: miRs and more." Leuk Lymphoma, 50, 502-505. IF 2.397

  19. Zenz, T., Mertens, D., Dohner, H.& Stilgenbauer, S. (2008) "Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications." Leuk Lymphoma, 49, 864-873. IF 2.397

Book Chapters

  1. Bilan, V., Allegra, D., Kuchenbauer, F., Mertens, D. (2014) "In vivo processing assay based on a dual-luciferase reporter system to evaluate DROSHA enzymatic activity." in miRNA Maturation, Arenz, C., ed. (Humana Press), 87-93, 2014

  2. Bloehdorn, J., Rouhi, A., Dhanyamraju, P., Krowiorz, K., Schneider, E., Langer,C., Mertens, D., Stilgenbauer, S., Kuchenbauer, F. (2013) "MicroRNAs in hematologic malignancies." in Non-coding RNAs and Cancer, Fabbri, M., ed. (Springer Science & Business Media), chapter 5.2

to top
powered by webEdition CMS